Study of DITPA in Patients With Congestive Heart Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-12-31

Study Completion Date

2006-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess the safety and efficacy of DITPA relative to placebo in patients with New York Heart Association (NYHA) class III or IV congestive heart failure (CHF) who have low serum T3. DITPA is an investigational agent.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Thyroid Hormone Analog to Fight Heart Failure: Phase II Trial (DITPA)

NCT00032643

Congestive Heart Failure

TERMINATED PHASE2

A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic Receptor Autoantibodies

NCT01798745

Heart Failure

WITHDRAWN PHASE2

Developing Oral LT3 Therapy for Heart Failure - HFpEF

NCT04111536

Heart Failure With Preserved Ejection Fraction Low Triiodothyronine Syndrome

COMPLETED PHASE1/PHASE2

Effects of Triiodothyronine (T3) in Ischemic Heart Failure

NCT05384847

Heart Failure

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF)

NCT01481402

Heart Failure Low T3 Syndrome

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale: Congestive heart failure (CHF) is a major public health problem associated with significant morbidity and mortality in patients with New York Heart Association (NYHA) class III or IV disease. Multiple studies have identified a particularly high-risk group of patients who have reduced thyroid hormone activity, specifically, low serum triiodothyronine (T3) levels. This group represents approximately 30% of patients with NYHA class III or IV disease and has significantly higher mortality rates than those with normal T3.

DITPA (3,5-diiodothyropropionic acid) is an analogue of naturally occurring thyroid hormone (T3) that has been specifically designed to improve cardiac performance with a lower potential for tachycardia in CHF patients. Although structurally similar to T3, DITPA has a propionic acid side chain and lacks an iodine at the 3' position of the outer phenolic ring. While DITPA binds to the same thyroid hormone receptors as T3, binding affinities are significantly less, suggesting partial agonistic actions. Preclinical studies with DITPA have supported a rationale for its use in patients with CHF.

Primary objective: To assess the safety and tolerability of DITPA in patients with NYHA class III/IV CHF and low serum T3.

Secondary Objective: To obtain preliminary evidence of the efficacy of DITPA in patients with NYHA class III/IV CHF and low serum T3

Design: The multi-center, randomized, double-blind, placebo-controlled study is designed to evaluate the safety and tolerability of DITPA in patients with NYHA class III or IV CHF who have low levels of serum T3 with normal levels of thyroid stimulating hormone (TSH).

One hundred and fifty patients at approximately 35 centers in the U.S. will be randomized to 1 of 3 treatment groups in a 1:1:1 ratio (i.e., 50 patients per treatment group):

* DITPA at 180 mg/day (90 mg twice a day \[BID\], orally)
* DITPA at 360 mg/day (180 mg BID, orally)
* Placebo BID, orally

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure, Congestive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Greater than or equal to 18 years of age
* NYHA class III or IV CHF
* Females must not be pregnant or lactating. Females of childbearing potential and males must use a reliable means of contraception
* Serum total T3 \<= 95 ng/dL with normal levels of TSH
* On a regimen consisting of angiotensin-converting enzyme inhibitors and/or angiotensin receptor antagonists, beta blockers, and diuretics for a minimum of 3 months prior to randomization
* Clinically stable for 2 weeks prior to randomization (defined as no change in functional class by NYHA, no hospitalization or ER visit, and no intravenous inotropic or vasodilator treatment for 2 weeks)
* An LVEF \<= 40%, documented within 6 months prior to randomization, or \> 6 months with confirmation of LVEF by local echocardiographic measurements within 2 weeks prior to randomization
* Able to give informed consent

Exclusion Criteria

* New onset CHF (less than 3 months prior to randomization)
* Active myocarditis, hypertrophic cardiomyopathy, uncorrected primary valvular disease, restrictive cardiomyopathy, uncorrected congenital heart disease, or constrictive pericarditis
* Myocardial infarction, unstable ischemic heart disease, stroke, or coronary revascularization procedure within 4 weeks prior to randomization; or an expectation of a coronary revascularization procedure, cardiac transplant, or left ventricular assist device placement being needed within 24 weeks after randomization
* History of sudden arrhythmic syncope or sustained ventricular arrhythmia, unless the patient has an implantable cardioverter defibrillator (ICD) for at least 12 weeks prior to randomization; history of clinically significant heart block, unless the patient has had a pacemaker at least 12 weeks prior to randomization
* History of cardiac resynchronization therapy in the last 12 weeks prior to randomization or expectation of cardiac resynchronization therapy or ventricular mechanical assistance needed within 24 weeks after randomization
* History of cardiac transplant
* Heart rate \< 50 beats per minute or \> 130 beats per minute
* Systolic blood pressure \<= 80 mm Hg
* Serum creatinine =\> 2.5 mg/dL
* Treatment with intravenous vasodilators (including nesiritide) or inotropes within 2 weeks prior to randomization
* Receipt of any other investigational agent or device within 4 weeks prior to randomization
* Diagnosis of other non-cardiac underlying medical conditions expected to impact their mortality within 24 weeks after randomization
* Drug or alcohol dependence, or other conditions which may affect study compliance
* History of thyroid disorders of any form within 24 weeks prior to randomization
* Use of thyroid supplements (levothyroxine, liothyronine, etc.) or any preparation containing thyromimetic agents within 24 weeks prior to randomization
* Supraventricular arrhythmia refractory to conventional treatment, as judged by the investigators

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No